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Regulation of pro-resolving biological systems in rheumatoid arthritis 
-investigations on the melanocortin system and resistin-  
Rheumatoid arthritis (RA) is a debilitating, autoimmune disease affecting about 1% 
of the population in western countries. In RA, auto-reactive T cells expand in the 
synovium, where they induce inflammation, leading to cartilage damage and bone 
resorption. There is no cure for RA. Despite biologic disease modifying agents, have 
improved disease outcome, severe rheumatoid arthritis can still cause physical 
disabilities and 40% of RA patients do not respond satisfactorily to treatment. Due 
to these shortcomings and the hazards of life-long immunosuppressive treatment, we 
attempted to explore the basis for curative induction of immune tolerance in RA. 
The melanocortin system consists in five melanocortin receptors 
(MC1-5R) and their ligands, α-, β- and γ-melanocyte stimulating hormones (α-, β- 
and γ-MSH), and corticotropin (ACTH), all derived from a common precursor 
protein: pro-opio-melanocortin (POMC) peptide. The MCRs are present in many 
tissues including the central nervous system and control varied bodily functions, 
such as pigmentation, libido and hunger. MCR and POMC genes and proteins are 
also expressed in cells of the immune system, exerting anti-inflammatory, tolerance 
inducing and pro-resolving actions. MCR expression is stimulated by the 
melanocortins, the synthesis of which is upregulated by inflammatory cytokines and 
inhibited by TGF-β. Interestingly, in animal experiments stimulation of MCRs in 
effector CD4+T helper (Th) cells and CD8+ T cytotoxic (Tc) cells turned these into T 
cells with regulatory function. 
VIII 
 
In this study, we wanted to explore the possibilities of inducing 
immune tolerance to auto-antigens based on the melanocortin system in RA. To this 
end, we searched for signs of melanocortin signaling in leukocyte subtypes in RA by 
measuring changes in MC1-5R gene expressions as a result of adalimumab induced 
normalization of the cytokine environment.  
Our findings unanimously pointed at regulated melanocortin 
signaling in leukocyte subsets in RA. Thus, in RA patients responding to TNFα 
inhibition, MCR gene expressions reacted with a differentiated fall, while increasing 
in a non-responding patient. Significant fall in MC2,3,4 and 5 R gene expressions 
was found in cytotoxic T cells and in B-cells. Strong associations between changes 
in disease driving cytokine and MCR gene expressions in cytotoxic T cells and 
helper T cells, indicated a central role for the melanocortin system in the disease 
process. 
Resistin is a recently detected, cytokine with pleiotropic effects. 
Originally, resistin was found to be produced by murine adipocytes and induce 
resistance to insulin. In man, resistin is primarily synthesized by monocytes and 
exerts pro-inflammatory, fibrogenic and regulatory functions. In our RA patients, 
TNFɑI resulted in a significant fall in resistin gene expression in monocytes and 
helper T cells. Change in gene expressions of resistin and TGF-β in monocytes 
correlated, supporting the perception of fibrogenic and regulatory roles. 
In summary, our results point at a future role for both the 




Regulering af naturligt forekommende anti-inflammatoriske processer 
ved leddegigt, -undersøgelser af melanocortin systemet og resistin-. 
Leddegigt (Reumatoid artrit (RA)) er en invaliderende autoimmun sygdom, der 
rammer omkring 1% af befolkningen i de vestlige lande. Ved RA findes auto-
reaktive T-celler, der migrerer til leddenes synovium, hvor de inducerer 
inflammation der medfører bruskskader og knoglenedbrydning. Der findes ingen 
helbredende behandling for RA. I de seneste år er der kommet nye behandlinger 
med biologiske lægemidler, der reducerer forekomsten af led forandringer ved RA. 
Fyrre procent af RA patienter responderer ikke tilfredsstillende på de kendte 
behandlinger og der er stadig RA patienter, der får svære fysiske handicaps. Med 
dette in mente og de risici, der er forbundet med livslang immunsupprimerende 
behandling, har vi udforsket melanocortin systemet og resistin med henblik på at 
inducere immuntolerance. 
Det humane melanocortin system består af 5 receptorer: melanocortin receptor 1-5 
(MC1-5R) og disses ligander α-, β- og γ-melanocytstimulerende hormoner (α-, β- og 
γ-MSH), og corticotropin (ACTH); som stammer fra precursorn: pro-opio-
melanocortin (POMC) peptid. MC1-5R findes i mange forskellige celler og væv, 
inklusiv centralnervesystemet. Melanocortin systemet har betydning for så 
forskellige funktioner som pigmentering, libido og sult. MC1-5R og POMC gener 
og proteiner er også udtrykt i immunsystemets celler, hvor systemet udøver sine 
anti-inflammatoriske, pro-resolverende og tolerance inducerende virkninger. 
MCR’erne opreguleres af melanocortinerne, hvis syntese stimuleres af pro-
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inflammatoriske cytokiner og inhiberes af TGF-β. Interessant er det, at stimulering 
af MCR på CD4+ T helper celler og CD8+ T cytotoksiske celler, forvandler cellerne 
til T celler med regulatorisk funktion, in vivo. 
I dette studie ønskede vi at udforske grundlaget for at inducere 
immun tolerance mod auto-antigener med hjælp af melanocortin systemet ved RA. 
Med dette mål for øje søgte vi efter beviser for melanocortin signalering i forskellige 
leukocyt subtyper ved RA. Dette ved at måle forandringer i MC1-5R genudtryk til 
følge af adalimumab induceret normalisering af cytokinmiljøet. 
Vores resultater pegede på, at melanocortin systemet reguleres i 
forskellige leukocyt subtyper ved RA. Hos RA patienter, der responderer på TNFα 
inhibering faldt MCR genudtrykket, medens MCR genudtrykket steg hos non-
responder. Vi fandt desuden at MC1-5R genudtrykkene reguleres nuanceret i 
forskellige typer af leukocytter. MC2-5R genudtrykket faldt signifikant i T 
cytotoksiske celler og B celler. Yderligere var der stærke korrelationer mellem 
forandringer i genudtrykket af sygdomsdrivende cytokiner og MC1-5R i T 
cytotoksiske celler og T helper celler, hvilket tyder på at reguleringen af 
melanocortin systemet er nært knyttet til sygdomsprocessen ved RA. 
Resistin er et nyligt opdaget cytokin med pleiotrope virkninger. 
Oprindeligt blev resistin påvist i fedtceller fra mus, hvor resistin øgede 
insulinresistensen. Hos mennesket derimod, dannes resistin frem for alt i monocytter 
og udøver pro-inflammatoriske, fibrosedannende og immunregulatoriske virkninger. 
I vores studie resulterede TNFα inhibering i et signifikant fald i resistin 
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genudtrykket i monocytter og T hjælper celler. Vi fandt desuden en korrelation 
mellem forandringer i resistin og TGF-β genudtrykket i monocytter. Dette fund 
støtter hypotesen om, at resistin har fibrotiserende og immunregulerende 
egenskaber. 
Sammenfattet peger vores resultater på en mulig rolle for både melanocortin 
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1. REVIEW OF THE LITTERATURE  
 Rheumatoid Arthritis  
1.1.1. Introduction 
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic 
inflammation and loss of self-tolerance. In RA, the auto-reactive immune system 
mounts a cellular Th1 response, but with important participation of the humoral Th2 
response, as RA is also characterized by the presence of auto-antibodies.  
In western countries, RA affects about 1% of the population with a 
female:male ratio of approximately 4:1 (Silman 2002). RA is characterized by 
synovial inflammation and hyperplasia, cartilage and bone destruction (Koch 2007), 
typically  located to  the peripheral joints symmetrically, especially to the small 
joints of the hands and feet. Extra-articular organ involvement such as pleurisy, 
pericarditis, cutaneous rheumatoid nodules, interstitial lung disease, vasculitis and 
secondary Sjögrens syndrome as well as systemic manifestations such as cardio-
vascular disease and fatigue are especially frequent in patients with auto-antibodies. 
Other features are morning stiffness and elevated inflammatory markers such as C-
reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as well as 
inflammation induced anemia and auto-antibodies, especially rheumatoid factor 
(RF) and anti-citrullinated protein antibodies (ACPAs). 
The diagnosis of RA is based on the criteria settled by the American 
College of Rheumatology (ACR) in 1988 (Table 3.1) (Arnett 1988) and by 
ACR/European League Against Rheumatism (EULAR) in 2010 (Aletaha 2010). As 
1988’s ACR criteria included late disease manifestations i.e. joint erosions and 
 
9 
rheumatoid nodules (table 3.1), they were found insufficient in the diagnosis of early 
RA. To meet the demands of modern early treatment, new diagnostic criteria were 
established (Table 1.1). 
 




1. Morning stiffness Morning stiffness in and around the joints, lasting 
at least one hour before maximal improvement 
2. Arthritis of 3 or more 
joint areas 
At least three joint areas simultaneously have had 
soft tissue swelling or fluid observed by a 
physician. (PIP, MCP, wrist, elbow, knee, ankle, 
and MTP joints) 
3. Arthritis of hand joints At least one area swollen in a wrist, MCP, or PIP 
joint 
4. Symmetric arthritis Simultaneous involvement of the same joint areas 
on both sides of the body  
5. Rheumatoid nodules Subcutaneous nodules, over bony prominences, or 
extensor surfaces, or in juxta-articular regions, 
observed by a physician 
6.  Serum rheumatoid 
factor 
Demonstration of abnormal amounts of serum 
rheumatoid factor  
7. Radiographic changes Postero-anterior hand and wrist radiographs 
showing juxta-articular bony decalcification or 
erosions  
Table 1.1:  For classification purposes, a patient shall be said to have rheumatoid arthritis if 
he/she has satisfied at least 4 of these 7 criteria. Criteria 1 through 4 must have been present 












Table 1.2. 2010 ACR/EULAR classifications criteria for RA 
Classifications criteria for RA.  
A. Joint involvement (0-5)  
• 1 large joint 
• 2-10 large joints 
• 1-3 small joints 
• 4-10 small joints 






B. Serology (0-3)  
• Negative RF and negative ACPA 
• Low-positive RF or low-positive ACPA 




D. Duration of symptoms  
• < 6 weeks 
• ≥ 6 weeks 
0 
1 
D. Acute-phase reactants (0-1)  
• Normal CRP and normal ESR 
• Abnormal CRP or abnormal ESR 
0 
1 
A score ≥ 6 points is required for classification as definite RA. RF = rheumatoid 
factor.  ACPA = anti-citrullinated protein antibodies.  ESR = erythrocyte sedimentation 
rate.  CRP = C-reactive protein 
 
1.1.2. Etiology and Pathogenesis 
RA results from a complex interaction between genes and environment, leading to a 
breakdown of immune-tolerance. 50 % of risk of developing RA is attributable to 
genetics. Especially factors influencing antigen presentation, T-cell and B-cell 
activation are involved. The antigen binding major histocompatibility complex 
(MHC)II, expressed on antigen presenting cells (APCs) consists in an alpha- (DRA) 
and a beta chain (DRB). Out of hundreds of different HLADRB1 alleles available, 
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the DRB1 chains that increase the risk of RA, share a sequence of amino acids in the 
antigen binding groove, the so-called shared epitope. Although about 100 single 
nucleotide polymorphisms (SNPs) in the genome associate with RA, only SNPs in 
the protein tyrosine phosphatase, non-receptor type 22 (PTPN22) gene is related to 
disease activity (Balsa 2010). PTPN22 affects the responsiveness of T-and B-cell 
receptors (Bottini 2014).  
Even environmental factors, especially smoking, influence the risk. 
Smoking may promote citrullination of lung proteins, leading to the synthesis of 
antibodies against citrullinated proteins (ACPA)s, that cross-react with similar 
proteins in the joints (Ytterberg 2015). In line with this, MHCIIs with shared epitope 
have been suggested to favor the presentation of citrullinated proteins, leading to 
auto-immunity (Hill 2003, Auger 2005). 
The hallmark of RA joint involvement is synovial cell hyperplasia 
and proliferation forming an invasive pannus at the cartilage-bone border, resulting 
in bone destruction. Prior to this, however, APCs i.e. dendritic cells, macrophages 
and B-cells by presenting self-antigens have activated T and B cells. Consequently, 
CD4+ and CD8+ T cells are thought to invade the synovium and through the 
synthesis of interferon gamma (IFNγ) and IL-17 attract and activate 
monocytes/macrophages, promoting synovial cell transformation into invasive 
fibroblast like synoviocytes as well as osteoclastogenesis (Choy 2012). Synovial 
germinal centers may be formed, where further activation of T- and B-cells can take 
place (Takemura 2001). 
 
12 
Activated macrophages produce large quantities of inflammatory 
cytokines TNF-ɑ, IL-1 and IL-6 that maintain inflammation as well as 
osteoclastogenesis. Fibroblast-like synoviocytes beyond producing inflammatory 
cytokines, release prostaglandins and matrix metalloproteinases (MMPs), promoting 
bone degradation and cellular invasion. Attracted granulocytes release their granule 
content of tissue damaging enzymes, especially myeloperoxidase (MPO) and 
MMP9. Furthermore, NETS produced by neutrophils may represent a source of 
epigenetically modified auto-antigens stmulating the production of ACPAs 
(Corsiero 2016). Invading B-cells contribute to the inflammatory process by the 
synthesis of RF and ACPA forming large immunocomplexes,that further stimulate 
cytokine production (Choy 2012). 
 
1.1.3. Measurement of Disease Activity and Severity 
1.1.3.1 Health Assessment Questionnaire for Rheumatoid Arthritis 
The Health Assessment Questionnaire (HAQ), introduced in 1984 (Meenan 1984) 
ascertains disease activity based on the patients´ own experience. The HAQ assesses 
20 difficulties in daily living on a 4-point Likert scale and groups these into 8 
functional categories. Each category gives a single score equal to the maximum 
value of their component activities (0, 1, 2, or 3). The higher the score, the more 
compromised function. The HAQ has been found a reliable predictor of long-term 
outcomes, i.e mortality, work disability and economic loss (Leigh 1991, Young 
2000, Maska 2011).  
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1.1.3.2 Disease Activity Score 28 
The Disease Activity Score 28 (DAS28), developed by EULAR, measures disease 
activity in RA. DAS28 ranges from 2.0 to 10.0, higher scores meaning more active 
disease (Prevoo 1995). A value below 2.6 is consistent with remission and above 5.1 
with high disease activity. Twenty-eight is the number of joints evaluated as to 
tenderness (TEN28) and swelling (SW28). The patient estimates global health on a 
visual analogue scale (VAS global) between 0 and 100, where 100 is the worst 
imaginable.  
DAS28 is calculated based on CRP as follows: 
DAS28-CRP = 0.56 X √(TEN28) + 0.28 X √(SW28) + 0.36 X ln(CRP+1) + 0.014 
X VAS Global + 0.96  
The formula above is used in our studies and in the Danish database “Danbio” 
including patients receiving treatment with biologic disease modifying drugs 
(bDMARDs). DAS28 is neither an exact nor exhaustive measure of disease 
processes as synovitis in the feet and ankles is not included and chronic pain as well 
as joint tenderness is weighted twice as high as synovitis. Yet, DAS28(CRP) is a 
strong predictor of disease progression. 
1.1.4. ACPA 
In 1998 for the first time, antibodies against proteins containing posttranslationally 
modified arginine, namely citrulline, were defined in RA. The antibodies related to 
RA with a good sensitivity and a very high specificity (Schellekens 1998). Because 
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of indications that the well-known anti-keratine (AKA) and anti-perinuclear factor 
antibodies (AFPA) were targeting citrullinated fillagrin in keratinocytes, antibodies 
were searched for by means of a library of synthetic citrullinated fillagrin 
derivatives. It was demonstrated that the presence of anti-cyclic citrullinated protein 
(anti-CCP) antibodies and AKA/AFPA coincided in RA patients (Schellekens 
1998). The former tests for AKA/AFPA were very inconvenient and therefore not in 
common use. Because AKA/AFPA had been demonstrated in preclinical RA (Kurki 
1992), a pathogenetic role for anti-CCP antibodies in RA was suspected. A later 
examination of a Swedish cohort of RA patients, who had had blood samples taken 
several years prior to disease debut as part of a regional health program, supported 
the findings by Kurki (Rantapaa-Dahlqvist 2003).  
In the following years antibodies to a long array of citrullinated 
proteins such as vimentin, enolase, fibrinogen derivatives etc. were discovered and 
the name changed to anti citrullinated protein antibodies (ACPAs). In recent time a 
pathogenetic role for ACPAs has been searched for. Evidence has accumulated that 
several factors harmful to bodily tissues, such as smoking (Mahdi 2009), silica- 
(Stolt 2010) and dust inhalation (Too 2016) as well as high physical workload (Zeng 
2017) promote citrullination of proteins in the lungs and other organs, functioning as 
antigenic epitopes for the development of ACPAs. These findings have led to the 
theory that immune cells recognizing citrullinated proteins in the lungs migrate to 
the joints, where they are reactivated by local citrullinated epitopes, resulting in a 
fierce immune reaction, leading to the well-known bone destructive synovitis found 
in RA (Snir 2010).  
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1.1.5. Pharmacological Treatment of Rheumatoid Arthritis 
There is no cure for RA. The goal of treatment is to achieve remission, minimizing 
joint damage, and enhancing physical function and quality of life. The strategy 
includes early diagnosis, the use of DMARDs and the aim “treat to target”, i.e the 
goal of the treatment is no arthritic joint. 
Four classes of drugs are used: non-steroidal anti-inflammatory 
drugs (NSAIDs), corticosteroids, conventional (c)DMARDs and bDMARDs. 
NSAIDs and corticosteroids act immediately, while the clinical effects of DMARDs 
appear after several weeks. Glucocorticoids are used systemically and/or intra-
articularly for flares and as a “bridging” therapy.  
Methotrexate (Mtx) is the cornerstone cDMARD and is 
recommended as first line therapy in moderate to high disease activity. Improvement 
is expected in 6-12 weeks. Methotrexate prevents pyrimidine and purine syntheses 
and consequently inhibits proliferation of immune cells.  Other cDMARDS used are: 
sulfasalazine, leflunomide and antimalarials. 
Biological DMARDS are increasingly used in the treatment of RA 
resistant to cDMARDs. They target specific steps in the inflammatory process and 
rapidly suppress disease activity. Of bDMARDs, tumor necrosis factor alpha 
(TNFα) inhibitors (I) were invented first. Five different TNFαI are available: 
etanercept, infliximab, adalimumab, certolizumab and golimumab. Etanercept is a 
fusion protein, joining the TNF receptor (R) to the Fc part of IgG1. The other 
TNFɑIs are monoclonal antibodies (mAbs), -the newest of them humanized- that 
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neutralize soluble and membrane bound TNF, preventing interaction with the 
TNFRs. Other bDMARDs act on other targets. Tocilizumab binds IL-6R, rituximab 
causes B-cell depletion by binding to CD20, abatacept, a fusion protein between 
CTLA-4 and the Fc region of IgG1, prevents co-stimulation of T-cells. Lately, small 
molecule, janus kinase (JAK) inhibitors, such as tofacitinib, have been found 
effective in RA (Tanaka 2012). 
1.1.5.1 Adalimumab. 
Adalimumab is the TNFαI used in our study. Adalimumab (Humira®) is a 
recombinant, fully humanized IgG1 mAb specific for human TNFα. It is approved 
by the European Medicines Agency and U.S. Food and Drug Administration, for 
treatment of moderately to severely active RA. 
Adalimumab blocks the interaction of TNF-α with its cell surface 
receptors TNFR1,2 by binding to soluble and membrane-bound TNFα. Adalimumab 
blocks TNFɑ signaling, which via a series of events involving several adaptor 
proteins activates the phosphorylation of inhibitory nuclear factor kappa B (IĸB), 
leading to its degradation and the release of transcription factor NFĸB, which then 
translocates to the nucleus and initiates the inflammatory cascade by transcribing the 
genes of inflammatory cytokines, chemokines, adhesion molecules, inducible nitric 
oxide synthase, metalloproteinases a.o. (Gravestein 1998). The aim of adalimumab 
treatment is to achieve physiological levels of TNFɑ in blood and inflammation 
sites, as abnormally low levels favor infections and tumor cell growth. 
Forty mg adalimumab given as a subcutaneous injection every other 
week should induce a rapid reduction in synovitis. Absorption and distribution of 
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adalimumab are slow, resulting in a smooth concentration-time profile (Nestorov 
2005). The effects of adalimumab and two other TNF-α inhibitors i.e. etanercept and 
infliximab in combination with methotrexate or leflunomide, have been found to be 
equal (De Stefano 2010). 
1.1.6. Immune Cells in RA  
1.1.6.1 T helper Cells, -CD4+ Th1, 2, 17, 22 and CD4+CD25+Regulatory T 
cells- 
T helper (Th) cells express the surface protein CD4 in close proximity to the T cell 
receptor (TCR) and are referred to as CD4+ Th cells. The CD4 glycoprotein is 
necessary for binding of the TCR to the MHCII antigen complex on the surface of 
APCs and for the amplification of the signal created thereby. CD4+T cells develop in 
the thymus and migrate to peripheral tissues. Encounter with their specific antigen 
activates CD4+ T cells to become cytokine secreting effector Th or T regulatory 
(Treg) cells. Helper T cells are named so, because one of their main roles is to 
activate the immune cells, most appropriate, to kill the infectious intruder in 
question, by means of cytokine secretion. The importance of functioning CD4+ Th 
cells has been made obvious by HIV infections, in which CD4+ Th cells are 
depleted. Subtypes of CD4+Th cells may be characterized by their cytokine profile 
and their expression of specific transcription factors and homing receptors.  
In 1986 the Th1/Th2 paradigm was proposed based on the findings 
in mice and is used to explain how the host elicits an adequate adaptive immune 
response (Mosmann 1986). Thus, Mosmann et al found that CD4+ Th cells can be 
divided into two distinct lineages based on their cytokine profile: Th1 cells, which 
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by producing interferon gamma (IFNγ) activate the cellular immune response, 
including monocytes and cytotoxic CD8+ T cells, which kill intracellular pathogens 
and the Th2 cells, which by the production of IL-4 stimulate B-cell proliferation, 
maturation, immunoglobulin production and Ig class switch, in order to clear 
extracellular pathogens. 
In recent years, Th cell types with other functions have been 
identified: Th17, regulatory T cell (Treg), Th22, Th9, and T follicular helper (Tfh) 
cells. Th17 cells support cellular immunity by secreting IL-17, Tregs support 
immune tolerance by the secretion of IL-10 and by the secretion and expression of 
membrane bound TGFβ. 
Th17 cells were first characterized in 2005-2006 (Harrington 2005, 
Betteli 2006) as IL-17 producing CD4+ Th cells with tissue injuring abilities in 
autoimmune diseases. About the same time point regulatory T cells (Tregs) were 
defined as CD4+CD25+Foxp3+ Th cells with tissue preserving and immune tolerance 
inducing properties (Sakaguchi 1995, 2003). Both cell types demanded the presence 
of TGFβ for their differentiation. However, while both TGFβ and IL-6 were needed 
for the development of Th17 cells, Treg differentiation was inhibited by the 
presence of IL-6.  In this way a dichotomy between the generation of autoimmunity 
and tissue harming Th17 cells and immune tolerance inducing Tregs cells was 
demonstrated. As the only CD4+ T cell, Tregs express the transcription factor Foxp3. 
Experiments have shown that induction of Foxp3 expression and IL-17 production 
in T cells are mutually exclusive (Betelli 2006).  
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For more than 25 years ago, several researchers concluded that Th1 
cells outnumbered Th2 cells especially in the synovium, but also in the blood of 
patients with RA. By cloning synovial membrane and synovial fluid CD4+T cells 
and examining their cytokine profile, almost all were found to produce IFNγ, not IL-
4 (Miltenburg 1992, Quayle 1993). These early findings still hold as in a recent 
work upon the production of granulocyte-macrophage stimulating growth factor 
(GM-CSF) by synovial and peripheral blood T cells in RA, the number of IFNγ 
producing Th1 cells dominated convincingly over Th2, Th17 and Th22 cells 
(Yamada 2017).  
For the last decade the Th1/Th2 paradigm in RA has been 
challenged by the Th17/Treg dichotomy. There seems to be no doubt that Th17 cells 
play a pathogenetic role in RA. Thus, an increased number of Th17 cells in 
peripheral blood and especially in synovial fluid correlating to DAS28 and CRP was 
demonstrated in RA, with an increased ratio of Th17/Th1 cells in peripheral blood 
and in synovial fluid of 0.10 and 0.40, respectively (Leipe 2010). Furthermore, Th17 
cells have been found to activate synovial fibroblasts to produce matrix 
metalloproteinases (van Hamburg 2011). IL-17 treated fibroblast like synoviocytes 
may furthermore upregulate RANKL (also called osteoclast differentiation factor) 
synthesis, thereby promoting osteoclastogenesis from monocytes and subsequent 
bone destruction (Kim 2015). 
The human immune system is potentially very harmful, and needs to 
be controlled by suppressor- cells and/or biologic regulatory systems. Absence or 
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malfunction of Tregs resulting in the deleterious immunodysregulation, 
polyendocrinopathy, enteropathy X-linked (IPEX) syndrome, consisting in a myriad 
of auto-immune disorders, clearly demonstrates their necessity. In RA, several 
researchers have found Tregs enriched in the synovial membrane (Cao 2003, Moradi 
2014,), while it is uncertain if the number Tregs is within normal limits in peripheral 
blood. Different mechanisms of malfunction of Tregs in RA have been proposed, 
like epigenetic changes of the CTLA-4 molecule, rendering suppression of effector 
T cells defective (Cribbs 2014).  
Lately, increased plasticity of Th17cells, meaning that Th17 cells 
transform into non-classical, IFNγ producing, Th1 cells was detected in RA 
synovium. Furthermore, it was proposed that these ex-Th17 cells were resistant to 
suppression by Tregs (Kotake 2017, Basdeo 2017). 
1.1.6.2 T Cytotoxic Cells 
T cytotoxic(c) lymphocytes express the surface protein CD8 and are referred to as 
CD8+ Tc cells. CD8+ Tc cells have primarily been perceived as effector cells in cell-
mediated immunity, with the ability to kill infected cells by means of granzyme B 
and perforin. However, Tc cells also seem to be involved in the pathogenesis of 
autoimmune diseases. 
CD8+ Tc cells, upon recognition of their specific antigen presented 
by the MHCI of infected cells, undergo expansion and mediate pathogen clearance 
by killing infected cells and secreting effector cytokines, which activate 
monocytes/macrophages. After this, the majority of CD8+ Tc cells dies by apoptosis, 
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leaving 5-10% behind as memory cells. IFN-γ is the key effector cytokine produced 
by CD8+ T cells. IFN-γ increases the sensitivity of infected cells to apoptosis. 
CD8+ Tc cells may play a greater role in RA pathogenesis and 
maintenance of RA than has been recognized. Although the principal purpose of 
CD8+ T cells is to protect the host from non-self and altered self, growing evidence 
implicates CD8+ Tc cells in the pathogenesis of autoimmune disorders, including 
RA, type 1 diabetes, systemic lupus erythematosus, multiple sclerosis, and 
inflammatory bowel disease (Kang 1999, Santamaria 2003, Babbe 2000, Brimmes 
2005). 
In the synovium, CD8+ Tc cells have been found prior to overt 
arthritis in persons producing RF and/or ACPA and have therefore been linked to 
the pathogenesis of RA. The presence of CD8+ Tc cells in the synovium correlated 
to the presence of ACPA in the blood and was more common in persons with more 
than one type of ACPA (de Hair 2014). Others found that IFN-γ production by 
circulating CD8+ Tc cells correlated to disease activity measured by DAS28 
(Carvalheiro 2015). These findings indicate that not only MHCII restricted CD4+ Th 
cells play a role in the pathogenesis and maintenance of RA.  
Interestingly, the promptness of IFN-γ synthesis by CD8+ Tc cells in 
virus infections decides which CD8+ Tc cells will dominate the later memory cell 
cohort (Liu 2004). Applying this finding to RA, the CD8+ Tc cells most suited for 
IFN-γ production upon auto-antigen recognition might dominate the memory Tc cell 
cohort and assure the maintenance of auto-immunity. 
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1.1.6.3 B Cells  
B cells are derived from multipotent stem cells in the bone marrow. Before the B 
cells enter the circulation, they undergo several maturation stages and express the B 
cell receptor (BCR). Although B cells reacting to self-antigens are cleared by clonal 
deletion in the bone marrow, auto-reactive, however often anergic, B-cells, may 
enter the periphery, where they will die. When an antigen is presented on the BCR 
to CD4+ T cells, dependent on antigen type and cytokine milieu, a Th2 response 
might be elicited, resulting in IL-4, IL-6 and IL-5 release, which instigates naïve B 
cells to proliferate and differentiate into antibody secreting plasma cells, affinity 
maturation and later on memory cell status.   
However, human B-cells may play several roles. B-cells are central 
to adaptive immunity, conducting several tasks, such as antigen presentation, T-cell 
activation, antibody production, cytokine synthesis, immune tolerance induction and 
ectopic germinal center establishment. B cells express several membrane molecules, 
among these CD19, which enhances the susceptibility to antigen stimulation by 
assembling with the BCR. 
There are several indications of a pathogenetic role for B-cells in 
RA. Thus, the removal of self-reactive B cells seems inappropriate in RA (Samuels 
2005). Moreover, levels of circulating B-cell activating factor (BAFF), which 
stimulates the survival of auto-reactive B cells and their production of RF and 
ACPA, are elevated (Moura 2011). Furthermore, B cells activate T-cells in the 
germinal centers of RA synovium (Vidard 1996) 
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  Considering cytokine synthesis, mRNA for several cytokines, such 
as IFN-γ, TNF-ɑ, IL-6, IL-10, IL-2, BAFF, RANKL and others have been 
demonstrated in human B-cells (Yeo 2011). 
As to tolerance induction, IL-10 and/or TGFβ producing regulatory 
B cell populations have been demonstrated in mice and humans (Iwata 2011). Cui et 
al found that the number of potentially IL-10 producing CD19+CD5+CD1dhi B cells 
is low in RA and correlates inversely with DAS28 (Cui 2014). 
1.1.6.4 Natural Killer Cells   
In 1975, NK cells were identified in mice as cells capable of killing leukemia cells 
without prior sensitization to antigens (Kiessling 1975). In man, natural killer cells 
are large, granular lymphocytes of innate immunity, that develop in the bone 
marrow and react to stressed, infected or cancer transformed cells. They are 
identified by the expression of the surface protein: neural cell adhesion molecule 
(CD56) and lack of the T cell co-receptor CD3. NK cells are equipped with both 
activating and inhibitory receptors, which interact in an intricate manner, including 
calibration to constitutional MHCI expression in different individuals and so-called 
licensing (Kim 2005). Activating receptors recognize signs of cell damage and/or 
infection, such as Fas ligand (L), viral ligands, tumor cell ligands and decrease in 
MHCI expression. NK cells express several inducers of apoptosis such as perforin 
and FasL. Moreover, Fc receptor expression allows NK cells to participate in 
antibody-dependent cell-mediated cytotoxicity (ADCC). NK cells are found in the 
lymphoid system, lung, liver, bone marrow, epithelial linings and other tissues. They 
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account for 10-15 % of lymphocytes in the blood. Their most important functions 
are cytotoxicity and cytokine production. Constitutionally high NK cell activity, due 
to efficient NK cell receptor interplay, may predispose to autoimmune disease, for 
example RA, by increased release of auto-antigens from killed cells (Yen 2001). 
NK cells may, through their ability to produce cytokines, direct the 
immune response. However, the role of NK cells in RA is controversial, and it is not 
established whether NK cells contribute to disease development or act to protect 
from tissue damage. Thus, Gulan et al reported an increased frequency of perforin 
expression as well as number of CD56+ NK cells in the blood, synovial fluid and 
synovium in RA. These cells had high perforin content per cell, except for NK cells 
in the synovial tissue (Gulan 2003). However, others have counted a low number of 
CD56+ NK cells in the blood of patients with active RA, increasing upon treatment 
with the bDMARD rituximab and correlating inversely with measures of disease 
activity (Lurati 2012). These findings are supported by a recent report, describing a 
lower number of circulating 56+ NK cells in RF and/or ACPA positive RA patients 
compared to seronegative RA. Moreover, NK cell apoptosis could be elicited by 
triggering of the FcγRIII, pointing at autoantibodies as the cause of low NK cell 






2. BIOLOGIC SYSTEMS WITH IMMUNE TOLERANCE 
INDUCING POTENTIAL 
 The melanocortin system 
2.1.1. The melanocortin 1-5 receptors 
The first melanocortin receptor (MC1R) was discovered in 1992 (Chhajlani 1992, 
Montjoy 1992), in the following years four more MCRs were sequenced (Chhajlani 
1993, Schiøth 1996, Gantz 1993). MCRs are seven-helix, small transmembrane G 
protein-coupled receptors, which activate the adenylate cyclase pathway, resulting in 
increased levels of intracellular cAMP. Moreover, MCR signaling results in 
inhibition of the degradation of IĸBɑ, leading to less NFĸB translocation to the 
nucleus and downregulation of the transcription of genes in the inflammatory 
cascade (Mandrika 2001). Each receptor is the product of a small, intronless gene. 
The MCRs are widespread in human tissues and cells, including the 
brain stem and influence so different physiological functions as skin pigmentation, 
corticosteroid synthesis, inflammation, hunger, sexual arousal and exocrine 
glandular secretion (Wikberg 2000, 2008 (reviews)). The melanocortin receptor 2 
(MC2R) only binds ACTH and is the adrenal gland ACTH receptor, but is also 
found in many immune cell types (Neumann-Andersen 2001, Andersen 2005). 
2.1.2. Melanocortins 
The ligands of the MCRs are the melanocortins, all derived from pro-opio-
melanocortin (POMC), which is split into α-, β-, and γ- melanocyte stimulating 




Figure 2.1. Melanocortin peptides, ACTH and α-, β-, and γ-MSH, derive from post-
translational processing of POMC. 
 
While MC2R binds ACTH only, the remaining MCRs bind ACTH and MSHs with 
differential affinity (table 2.1). The differences in affinity have been used to 
pinpoint, which MCR is responsible for cell functions, elicited by melanocortin 
stimulation. 
Table 2.1. Affinity of the melanocortins to melanocortin receptors. 
Receptors Bindings affinity for melanocortins 
MC1R Α-MSH = ACTH > β-MSH > γ-MSH  
MC2R ACTH 
MC3R γ-MSH = ACTH ≥ α-MSH = β-MSH 
MC4R Α-MSH = ACTH > β-MSH > γ-MSH 
MC5R Α-MSH > ACTH > β-MSH 
 
2.1.2.1 Anti-inflammatory Effects of MCR stimulation 
Melanocortin receptor expression has been reported in a wide range of human 
immunologically active cells, that is in neutrophils (Catania 1996), macrophages 
(Bhardwaj 1997), dendritic cells (Renalls 2010), CD19+ B-lymphocytes, CD8+ 
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cytotoxic T-cell and CD56+ NK cells (Neumann-Andersen 2001, Andersen 2005, 
Loser 2010), as well as in endothelial cells (Kalden 1999) and fibroblasts (Böhm 
1999). 
The actions of the melanocortin system in immune cells are 
predominantly anti-inflammatory, pro-resolving and immune tolerance inducing. It 
has been under debate, which MCR is the most important mediator of these effects. 
Thus anti-inflammatory effects mediated by MC1R have been reported in several 
human immune cell types. For example, in a MC1R expressing macrophage cell 
line, stimulation with ɑ-MSH decreased lipopolysaccharide (LPS) induced TNFɑ 
synthesis (Taherzadeh 1999). Under similar conditions, NFĸB nuclear translocation 
and nitrogen oxide (NO) release was reduced (Mandrika 2001). Furthermore, in a 
LPS stimulated endothelial cell line, ɑ-MSH reduced the expression of adhesion 
molecules significantly (Kalden 1999). Several steps in the inflammatory process, 
i.e. inflammatory cytokine production, vasodilation and leukocyte migration were 
thus inhibited by MC1R signaling.  
Lately, focus has been on the anti-ischemic effects of melanocortin 
signaling in models of ischemic reperfusion injury (IR) (Giuliani 2012). In an IR 
model in MC3R null mice, treatment with a selective MC1R agonist diminished 
tissue injury by decreasing leukocyte adhesion and migration (Leoni 2010). The aim 
of these studies was to develop selective MSH analogues to treat/prevent tissue 
injury in cardio- and cerebrovascular catastrophes. 
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Signaling through the MC3R has also been reported to elicit anti-
inflammatory effects. In an animal model of urate induced arthritis, neutrophil 
influx, increase in joint size, synovial fluid IL-1β and IL-6 synthesis were inhibited 
by injection of ACTH and γ-MSH, which is semi-selective for MC3R (Getting 
2002). In a model of peritonitis in a mouse strain with naturally defective MC1R 
similar results were achieved (Getting 2003). The anti-inflammatory, tissue-
preserving effects of MC1R and MC3R stimulation were found equal in a model of 
IR injury, as the response to treatment with a synthetic, MC3R selective γ-MSH 
analogue resembled the results achieved by the stimulation of the MC1R (Leoni 
2008). 
 
2.1.3. Immune Tolerance Induction by Melanocortin Signaling 
2.1.3.1 T-cells 
Evidence is accumulating, that melanocortin system signaling is able to induce 
immune tolerance. In early experiments, it was shown that MC1R signaling 
decreases CD86 expression in human monocytes (Bhardwaj 1997). As CD86 co-
stimulation is necessary as the second signal in T cell activation, a reduction in 
CD86 number might impede T cell auto-reactivity.  
Most interestingly however, it was found that MC5R signaling 
could induce immune tolerance in a murine model of auto-immune uveoretinitis. In 
this model, treatment of IFNγ producing effector CD4+ Th cells reactive to retinoid 
binding peptide with ɑ-MSH in the presence of auto-antigen presenting APCs, 
transformed the effector CD4+Th cells into TGFβ producing CD4+CD25+ Tregs 
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(Taylor 2001). This transformation was shown to proceed through MC5R signaling. 
Equally promising as to the induction of tolerance to auto-antigens are the findings 
in a study on murine experimental autoimmune encephalomyelitis (EAE), a model 
of multiple sclerosis. In this study myelin protein-specific T cells by ɑ-MSH gene 
bearing virus transfection were rendered transgenic for ɑ-MSH, thereby manipulated 
to produce ɑ-MSH. This maneuver caused transformation of the myelin protein-
specific effector Th1 into Treg cells, producing significantly less IFNγ and IL-2 and 
significantly more TGFβ. Also, injection of the ɑ-MSH transgenic myelin protein-
specific T cells resulted in far less EAE than the injection of their non-transgenic 
counterpart (Han 2007). 
Furthermore, even allergen sensitized CD8+ Tc cells seem amenable 
to immune tolerance induction by ɑ-MSH treatment as shown in murine models of 
contact hypersensitivity dermatitis (Grabbe 1996, Loser 2010). In one experiment, 
CD8+ Tc cells sensitized to 2,4-dinitro-fluorobenzene (DNFB) were treated with ɑ-
MSH in the presence of DNFB pulsed dendritic cells and transferred to mice with 
DNFB specific contact dermatitis. Upon cutaneous application of DNFB, these mice 
developed less ear swelling than controls (Loser 2010). Furthermore, unlike CD4+ T 






2.1.3.2 B Cells 
The reported effects of melanocortins on B cells seem contradictory, thus ACTH 
stimulated the functions of human tonsillar B-cells in the presence of IL-2 (Alvrez-
Mon 1985). In a murine pro-B-lymphocyte cell line, NDP-MSH, a potent synthetic 
ɑ-MSH analogue, stimulated JAK/STAT signaling and cell growth, probably via 
MC5R (Buggy 1998).  
Recently however, in a murine SLE model, NDP-MSH treatment 
reduced IgG1, IgG2a levels and ANA. In the glomeruli, IgG deposits, cellularity and 
expression of inducible nitric oxide synthase diminished, pointing at a suppressive 















Resistin is a peptide discovered in 2001 with hormone and cytokine properties. In 
mice, resistin is secreted by adipocytes and was named for its ability to induce 
insulin resistance in these (Steppan 2001). The origin and effects of resistin are 
however controversial in humans. Thus, resistin gene expression was found absent 
in human adipocytes, but could be demonstrated in monocytes (Nagaev 2001). In 
human peripheral blood monocytes (PBMCs), expression of resistin mRNA was 
markedly increased by the pro-inflammatory cytokines IL-1, IL-6, TNFɑ and by 
LPS (Kaser 2003). In turn, resistin, was found to exert pro-inflammatory effects 
such as upregulation of the gene expression and release of TNFɑ, IL-1β and IL-6 in 
human PBMCs, via NFĸB activation (Silswal 2005, Bokarewa 2005). Furthermore, 
resistin was found able to induce arthritis in mice (Bokarewa 2005) and levels were 
found elevated in RA synovial fluid, correlating with joint destruction (Bokarewa 
2005, Senholt 2007). TNFɑ inhibition has been demonstrated to decrease serum 
resistin levels in RA patients (Gonzales-Gay 2008).  
The presence of resistin mRNA and protein has scarcely been 
examined in other cell types than monocytes or PBMCs. However, in a study on 
differences in grade of inflammatory reaction between lean and obese asthma 
patients, resistin release by CD4+ T cells was demonstrated (Rojas-Dotor 2013). In a 
study on frequencies of CD4+ Th1, 2, 17, 22 and Treg subtypes in the healthy human 
intestinal tract, resistin gene expression was found to be enriched together with 
CD4+ Th17 cells in the cecum (Wolff 2012). In a co-culture of CD4+ T cells and 
DCs stimulated with resistin, gene expression for markers of Tregs, i.e. TGFβ, 
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CTLA-4 and FoxP3 increased as did the number of CD4+CD25+ Tregs (Son 2010). 
These findings point at a role for resistin in immune response direction and immune 
tolerance induction.  
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3. AIM OF THE INVESTIGATIONS 
The overall aim of the study was to explore whether immune tolerance inducing, 
pro-resolving, anti-inflammatory biological systems are activated in rheumatoid 
arthritis and amenable to changes in the cytokine environment. 
The more specific aims were to 
1. examine the impact of TNFαI induced normalization of the cytokine milieu 
in RA on MC1-5R gene expression in order to explore the possibilities of 
influencing melanocortin system activities in RA. 
 
2. examine the gene expression of resistin in leukocyte subsets not formerly 
examined, to achieve an improved understanding of resistin potentials. 
 
3. search for regulated MC1-5R gene expression in NK cells, as the functions 
of NK cells in RA are uncertain and MC1-5R may constitute a new 






4. METHODOLOGY  
4.1. Patients and Methods 
The present investigations were performed on lymphocyte subsets donated by 
patients with active RA. All patients gave their informed consent, orally and in 
writing. The study was approved by the Ethics Committee of Northern Jutland, 
Denmark, (N20100060).  
At the time of inclusion, the diagnosis was secured by clinical 
estimation of number of swollen and tender joints, standard blood samples including 
RF, ACPA and ANA. X-rays of the wrists, hands, feet and chest were performed.  
Patients with active RA, starting adalimumab treatment, were 
consecutively included according to the advice of the Danish ‘Council for Expensive 
Hospital Medicine’, which recommends bDMARD to RA patients with DAS28 
(CRP) ≥3.2 for more than 3 months, not responding to two cDMARDs or DAS28 
(CRP) >5.1 at two consecutive consultations. Seven patients, six females and one 
male, with definite RA according to the 2010 ACR/EULAR criteria (Alehtaha 2010) 
were included. Their mean age was 45.4 + 7.5 (mean + SD) years and mean disease 
duration 4.0 years (1–14 years). Six patients produced RF and ACPA. Median 
DAS28 (CRP) was 5.1 (4.3–6.7) [interquartile range (IQR)]. Patients with cancer, 




Peripheral blood samples were collected at two time-points: just 
before start and after three months of adalimumab therapy. 
Inflammatory activity was estimated by conventional laboratory 
tests such as CRP, hemoglobin, leucocytes with differential and platelets. Levels of 
rheumatoid factor and ACPA were measured by ELISA technique.  
4.1.1. Electronic Patient-Self-Reported Outcome (DANBIO)  
DANBIO is a nation-wide Danish database, which has been established with the aim 
to follow the use and results of bDMARD treatment in Danish patients with 
rheumatic diseases. Moreover, DANBIO allows patients with rheumatic disease to 
report their status before the consultation, thereby improving the communication 
with the rheumatologist and documenting rheumatic disease activity from the 
patient`s perspective. 
In our patients, demographic data such as age, sex, disease duration, 
co-morbidity and previous medication were registered in DANBIO at diagnosis.  
Just before the start of adalimumab treatment and at three months of 
therapy, the patients reported pain-, fatigue- and patient´s global on a 100 - mm 
visual analogue scale (VAS), as well as estimated their functional abilities in a 
health assessment questionnaire (HAQ), electronically, to DANBIO. At the same 
time-points, the examining doctor noted the number of swollen and tender joints, 
doctor´s global assessment as well as current medication in DANBIO.  
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Figure 4.1. The workflow of the laboratory experiments used herein. 
4.1.2. Isolation of Peripheral Mononuclear Blood Cells (PBMC)  
For cell isolation, 10 mL of whole blood was diluted 1:1 with PBS and subjected to 
Ficoll-isopaque (Lymphoprep, Nycomed, Oslo, Norway) gradient centrifugation. 
The interface containing PBMC was collected, diluted 1:5 with PBS and washed 
from Lymphoprep by centrifugation. Next, cells were resuspended in 1.5 mL 
Roswell Park Memorial Institute (RPMI) medium and left at 4 ºC overnight. Cells 
were counted and the concentration was adjusted to 106/mL using RPMI. 
Subpopulations of PBMC’s were separated by positive selection with specific 
monoclonal antibody-coated Dynabeads (Dynal, Oslo, Norway) according to the 




4.1.3. Study I and II: Monoclonal Antibodies  
All of the monoclonal antibodies used herein were purchased from DAKO A/S 
(Glostrup, Denmark). The specificities of the monoclonal antibodies were as 
follows: CD4, CD8 and CD19 and their negative isotype control were all IgG1 
isotype and derived from Mab/clone MT310, DK25, HD37 and DAK-G01, 
respectively. CD14 and its negative isotype control were of IgG2a isotype and 
derived from Mab/clone TUK4 and DAK-G05, respectively.  
4.1.4. Total RNA Extraction  
Lysates from CD4+, CD8+, CD14+ and CD19+ cell subsets (> 95 % purity) were 
used to extract total RNA by the acid guanidinum thiocyanate– phenol–chloroform 
method. 
4.1.5. Study III. Monoclonal Antibodies  
The monoclonal antibody against the IgG1 MY 31 isoform of neural cell adhesion 
molecule (NCAM, CD56), which defines the NK cell subset was purchased from 
Becton-Dickinson, Mountain View, CA, USA, while its negative isotype control 
IgG1 used herein was derived from Mab/clone DAK-G0, DAKO A/S Glostrup, 
Denmark.  
4.1.6. Total RNA Extraction.  
Lysates from CD56+ (> 95 % purity) were used to extract total RNA by the acid 
guanidinum thiocyanate-phenol-chloroform method. 
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4.1.7. Quantitative Reverse Transcription-Polymerase Chain Reaction  
Real-time qPCR analysis was used to examine changes in receptor and cytokine 
mRNA levels.  Real-time qPCR is a simple method, which gives reliable results. 
Messenger RNA levels provide information about the transcription of genes and 
changes in the regulation of transcription. 
We performed our custom gene expression analysis according to the 
MIQE guidelines (Bustin 2009). Lymphocyte subpopulations separated by positive 
Dynabead selection were used for total RNA extraction. Cell-bead pellet was 
resuspended in 10 µl of phosphate buffered solution (PBS), lysed in 350 µl of RLT 
lysis buffer (RNeasy Mini kit, QIAGEN, Germany) and kept at -80 ºC until further 
use. To make our tests as uniform as possible, we did RNA preparation, reverse 
transcription and overall quality assessment for all samples at the same time in the 
same experiment. The monoclonal antibody covered magnetic beads were removed 
prior to RNA extraction. RNA yield was on average 2005 ng in a total volume of 30 
µl, and purity on average A260/A280 was 1.7 assessed by NanoDrop ND-1000 
spectrophotometer (Thermo Fisher Scientific Inc., USA). For each sample, 400 ng 
of total RNA in reaction volume 20 µl was transcribed into cDNA by using random 
hexamer primers, MultiScribe™ MuLV reverse transcriptase, reaction buffer and 
dNTP mix (High-Capacity cDNA Reverse Transcription Kit, Catalog # 4368813, 
Life Technologies) according to the manufacturer´s manual. RNA integrity, 
inhibition testing, efficiency of reverse transcription and cDNA stability were 
evaluated by the constancy of threshold cycle (Ct) values for 18S rRNA in every 
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single RT-qPCR test. This is a classical reference gene as well as the rational quality 
indicator for the entire study. Therefore, as previously optimized and tested by the 
standard curve assessment, we used Eukaryotic 18S rRNA Endogenous Control 
(VIC®/MGB probe, primer limited, Catalog # 4319413E, Life Technologies) 
according to the manufacturer’s recommendations. Details for each TaqMan® 
Assay regarding sequence accession numbers and the targeted splice variants, 
location and length of amplicon as well as location and identity of any modifications 
can be retrieved on the producer’s web site www.lifetechnologies.com using assay 
ID (or official gene symbol) as next: Hs00267168_s1 (MC1R), Hs00300820_s1 
(MC2R), Hs00252036_s1 (MC3R), Hs00271877_s1 (MC4R), Hs00271882_s1 
(MC5R), Hs01555410_m1 (IL1B), Hs00961622_m1 (IL10), Hs00989291_m1 
(IFNG), Hs00174128_m1 (TNF), Hs04188773_g1 (LTA) and Hs99999918_m1 
(TGFB1), Hs00174103_m1  (IL8), Hs01003716_m1 (IL15) and Hs524809_ 
(RETN). Eukaryotic 18S rRNA (Catalog # 4319413E) (Thermo Fisher, Scientific, 
Inc.). However, in silico specificity screen by BLAST is impossible because the 
producer does not disclose the primer/probe sequences. We performed uniformly 
multiplexed tests with cDNA input equal to 5 ng of total RNA in 96-well plates and 
reaction volume 20 µl/well using 2x Universal Master Mix on a 7900HT instrument 
(all from Life Technologies) with factory default settings. Each plate included both 
the no template control (NTC) and the PMA/ionomycin-stimulated PBMC (sPBMC) 
as an internal positive control. The data were analyzed with a ddCt method resulting 
in relative quantities (RQ) comparative to a reference expression level in stimulated 
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PBMC that is equal to 1. Fold-change value is a result of division RQ after therapy 
by RQ before therapy. 
 Statistics 
Because of a rather small number of patients, Wilcoxon´s matched-pairs signed rank 
test for continuous data was used to evaluate differences in receptor and cytokine 
gene expression levels as well as disease activity variables before and after three 
months of adalimumab treatment. Thus, the patients served as their own controls. 
This set-up is advantageous as it eliminates confounding factors due to badly 
matched controls. 
Correlation analyses were performed using the non-parametric Spearman rank 
correlation test. All P-values were two-sided; P < 0.05 was considered significant. 
All statistical analyses were performed using the SPSS computerizing program 








5. RESULTS  
5.1. Results in Paper I-III 
In this result section, at first the effects of adalimumab treatment on disease activity 
in RA patients will be reported.  
Next the effects of adalimumab treatment on gene expressions of the 
biomarkers of interest, that is MC1-5R and resistin will be presented, then the 
effects on gene expression of context cytokines will be stated. Finally, correlations 
between fold changes in the gene expressions of the biomarkers of interest and the 
context cytokines will be explained. 
In these three original papers, TNFαI induced changes in gene 
expressions of the biomarkers of interest were related to changes in gene expressions 
of cytokines, representing important disease mechanisms in RA. The cytokines 
examined were: Th1 response cytokines: IFNγ and TNFβ; inflammatory cytokines: 
IL-1β and TNFɑ as well as regulatory cytokines: IL-10 and TGFβ.  
Fold change in gene expressions were examined in important 
disease driving immune cell subsets of adaptive immunity that is CD4+ Th cells, 
CD8+ Tc cells and CD19+ B cells as well as in CD14+ monocytes, representing 
innate immunity.   
In paper III, MC1-5R gene expression in another cell subset of innate immunity, 
namely the CD56+ NK cell subset was examined. 
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Effects of Adalimumab Treatment on Measures of Disease Activity in 
RA Patients  
All patients injected themselves subcutaneously with adalimumab in the form of 
Humira 40 mg every other week during all 3 months without interruption. 
Of the seven patients, six responded to treatment (Table 5.1). To 
avoid adverse effects, prednisolone was stopped after two weeks and cDMARDs 
were tapered when possible in accordance with disease activity. Methotrexate 
however, was continued to avoid anti-adalimumab antibody synthesis. If 
methotrexate was not tolerated, another DMARD was chosen. In two patients 
treated with sulfasalazine combined with leflunomide and methotrexate, 
respectively, sulfasalazine medication was stopped. The four patients, treated with a 
mean dose of 18.75 mg/week methotrexate at inclusion, continued this medication. 
Also the three patients taking leflunomide continued their medication.  
 DAS28 (CRP), HAQ, number of tender and swollen joints, pain 
and global VAS decreased significantly in patients with RA responding to 
adalimumab. Median C-reactive protein and ACPA level, neutrophil and platelet 
number decreased insignificantly.  
The non-responding patient was a 47-year-old male with RA since 
half a year with DAS28(CRP) 4.4, highly positive RF145 kIU/l(<10 kIU/ l) and 
highly positive ACPA >600 AE/l (<14 AE/l) at inclusion. This patient did not 
respond to adalimumab, despite combination with 25 mg methotrexate s.c. a week. 
At 3-months follow-up of adalimumab treatment, the patient had developed 
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rheumatoid nodules and had six tender and swollen joints. The patient was not 
smoking. 
Table 5.1. Characteristics of six patients with active rheumatoid arthritis, responding to TNF-
α inhibition 
 
VAS, visual analogue scale; Hgb, haemoglobin; DAS28CRP, 28 joints disease activity score, 
based on C-reactive protein; ACPA, anti-citrullinated protein antibody; CRP, C-reactive 
protein; HAQ, health assessment questionnaire. 
Results are shown as median values (interquartile range) before and 3 months after start of 
TNF-α inhibition. 




In paper I, entitled: “Melanocortin 2, 3 and 4 receptor gene expressions are 
downregulated in CD8+ T cytotoxic lymphocytes and CD19+ B lymphocytes in 
rheumatoid arthritis responding to TNFα inhibition”, we explored the 
differential reactions of MC1-5R gene expressions in CD4+ Th cells, CD8+ Tc cells, 
CD19+ B cells and CD14+ monocytes to adalimumab treatment in the context of 




Changes in MC1-5R Gene Expressions (figure 5.1) 
In cell subsets of adaptive immunity, our analyses showed downregulation of MC1-
5R gene expressions in CD8+ Tc cells and CD19+ B-cells. There was a significant 
downregulation of MC2R, MC3R and MC4R gene expressions in CD8+ Tc cells in 
RA patients responding to TNFɑI. The expressions of these MCR genes as well as 
the MC5R gene were also significantly downregulated in CD19+ B-cells from RA 
patients responding to TNFαI.  
In CD4+ Th cells, the transcription of all MCR genes, except for 
MC1R was downregulated in RA patients responding to therapy, however the 
changes did not reach significance.  
In the patient, not responding to TNFαI, MC1-5R gene expression 
increased impressively in all cell subsets of adaptive immunity. 
In innate immunity, i.e. in CD14+ monocytes, MC1-5R gene 
transcription decreased in the RA patients responding to adalimumab treatment, 
however the results were not significant.  
Also in the RA patient not responding to TNFαI, MC1-5R gene transcription in 




Figur 5.1. RT-qPCR analyses of MC1-5R, IFNγ, TNF-β, IL-1β, TNF-α, IL-10 and TGF-
β mRNAs in CD4+ Th ly, CD8+ Tc ly, CD19+ B ly and CD14+ monocytes, showing 
downregulation of mRNA expression upon treatment with adalimumab in responders and 
upregulation in the non-responder, preferentially. The data are presented as fold change in a 
logarithmic scale, where 1 denotes the expression before treatment, 0.5 denotes twofold 
decrease and 0.25 a fourfold decrease etcetera. 2 denotes a twofold increase and 4 a fourfold 





In paper II, entitled: “Resistin gene expression is downregulated in CD4+ T 
helper lymphocytes and CD14+ monocytes in rheumatoid arthritis responding 
to TNFα inhibition”, we examined the effects of adalimumab treatment on resistin 
(RETN) gene expression in cell subsets of innate and adaptive immunity in the 
context of Th1-, inflammatory- and regulatory cytokine gene expressions as outlined 
above.  
Changes in resistin gene expression (figure 5.2 and 5.3) 
We found that CD14+ monocytes contained the highest number of RETN gene 
transcripts of the examined leucocyte subtypes both before and during TNFɑI. In 
CD14+ monocytes RETN gene expression was significantly down-regulated in the 
six RA patients responding to TNFαI and up-regulated in the non-responding RA 
patient.  
In CD4+ Th cells RETN gene expression decreased significantly in RA patients 
responding to TNFαI, while in the non-responding patient there was a slight 
decrease. The RETN gene expression increased, however insignificantly, in CD8+Tc 
lymphocytes and CD19+ B lymphocytes from RA patients responding to therapy, 





Figure 5.2. (A) Relative resistin mRNA levels in CD14+ monocytes, CD4+ Th lymphocytes, 
CD8+ Tc lymphocytes and CD19+ B-lymphocytes in active rheumatoid arthritis. (B) Relative 
resistin mRNA levels in CD14+ monocytes, CD4+ Th lymphocytes, CD8+ Tc lymphocytes 
and CD19+ B-lymphocytes in rheumatoid arthritis before and during TNF-α inhibition. (C) 
Relative resistin mRNA levels in CD14+ monocytes, CD4+ Th lymphocytes, CD8+ Tc 
lymphocytes and CD19+ B-lymphocytes in rheumatoid arthritis patients responding to TNF-α 
inhibition. (D) Fold change in relative resistin mRNA levels in CD14+ monocytes, CD4+ Th 
lymphocytes, CD8+ Tc lymphocytes and CD19+ B-lymphocytes in rheumatoid arthritis due to 





Figure 5.3. Fold change due to TNF-α inhibition in RETN, IFN-γ, TNF-β, IL-1β, TNF-α, IL-
10 and TGF-β gene expressions in six patients with active rheumatoid arthritis, responding to 
treatment and one patient with active rheumatoid arthritis, who did not respond. Cytokine 
mRNA levels were measured before start of TNF-α inhibition and after 3 months of 
treatment. IFN-γ, interferon gamma; IL, interleukin; RETN, resistin; TNF-β, tumor necrosis 










In paper III, entitled: “Melanocortin receptor gene expressions in CD56+ NK cells 
from two rheumatoid arthritis patients respond to TNFα inhibition by 
adalimumab”, we examined the expression and differential reactions of MC1-5R 
gene expressions to adalimumab treatment in CD56+ NK cells from two patients 
with active RA. 
Changes in MC1-5R Gene Expressions (figure 5.4) 
MC1-5R gene expression was demonstrated in CD56+NK cells from two patients 
with active RA. MC4R gene expression for the first time was found to be present in 
human CD56+NK cells. Adalimumab treatment resulted in the downregulation of 
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Figure 5.4. Fold changes of melanocortin 1-5 receptor and cytokine gene expressions in 
CD56+NK cells in 2 RA patients, responding to adalimumab treatment. A. Real time RT-
qPCR analyses of MCR1-5, IFNγ, TNFβ, IL-1β, TNFα, IL-10, TGFβ, IL-8, IL-15 and resistin 
(RETN) mRNAs in CD56+ natural killer cells, showing down-regulation of mRNA 
expression upon treatment with adalimumab. The data are presented as fold change in a 
logarithmic scale, where 1 denotes the expression before treatment, 0.5 denotes two-fold 
decrease and 0.25 a four-fold decrease etcetera. B. Relative change in clinical sign and 
symptoms of rheumatoid arthritis activity presented as a ratio between the value after three 






PAPERS I, II and III 
Changes in Th1-response, Inflammatory and Regulatory Cytokine Gene 
Expressions (figure 5.1) 
Th1 Response Cytokines IFN-γ and TNF-β 
Th1 response cytokines IFN-γ and TNF-β gene expressions were downregulated in 
lymphocyte subsets of adaptive immunity, i.e CD4+ Th ly, CD8+ Tc ly and CD19+ B 
ly, in patients with RA responding to adalimumab. TNF-β gene expression 
decreased significantly in CD8+ Tc ly and tended to decrease significantly in CD4+ 
Th ly (P = 0.06).  
In the patient with RA not responding to adalimumab, IFN-γ and 
TNF-β gene expressions were upregulated in all examined cell subsets of adaptive 
immunity.  
Inflammatory Cytokines IL-1β and TNF-ɑ 
Inflammatory cytokine IL-1β and TNF-ɑ gene expressions were downregulated, 
however insignificantly, (except for a slight increase in IL-1β gene expression in 
CD19+ B cells), in lymphocyte subsets of adaptive immunity, in patients with RA 
responding to adalimumab. In the RA patient not responding to adalimumab, IL-1β 
and TNF-ɑ gene expressions increased in all cell subsets of adaptive immunity. 
In cells of innate immunity, i.e. CD14+ monocytes, the gene expressions of 
inflammatory cytokines IL-1β and TNF-ɑ decreased in patients with RA responding 
to adalimumab. Fall in IL-1b gene expression almost reached significance (P = 
0.06).   
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In the non-responding patient, the gene expressions of IL-1β and TNF-ɑ increased in 
monocytes. 
Regulatory Cytokines IL-10 and TGF-β 
In all examined cell subsets of adaptive immunity, regulatory cytokine IL-10 gene 
expression was downregulated, in CD4+ Th cells significantly, in patients with RA 
responding to adalimumab. In the non-responding patient, IL-10 gene expression 
increased in all cell subsets of adaptive immunity, except CD8+ Tc cells.  
In monocytes IL-10 gene expression was downregulated in patients 
responding to therapy and upregulated in the non-responding patient. 
TGF-β gene expression was downregulated in CD4+ Th and CD8+ 
Tc cell subsets and slightly upregulated in CD19+ B-cells due to TNFɑI in RA 
responding to therapy. In the non-responding patient TGF-β gene expression 
increased in all examined cell subsets of adaptive immunity. 
In CD14+ monocytes, TGF-β gene expression increased in both the 
responding and non-responding patients, however upregulation was more 







Correlations between Fold Change in MC1-5R, Resistin-, and 
Context Cytokine Gene Expressions 
Correlations between Fold Change in MC1-5R and Cytokine Gene 
Expressions (figure 5.5) 
The TNFαI induced fold change in MCR gene expressions correlated to fold change 
in IFNγ gene expression in the CD8+ Tc cell subset and to fold change in IL-1β gene 
expression in CD4+ Th cells. The correlations, we found between TNFαI induced 
fold change in gene expressions between MC1-5R and cytokines, are in accordance 
with previously described mechanisms, regulating MC1-3R and MC5R gene 
transcription. Thus, MCR gene expression in various cells and tissues is stimulated 
by their ligands, i.e the melanocortins. The synthesis of melanocortins in turn is 




Figure 5.5.  A. Correlations between fold change in MC1-5R and IFN-γ mRNA levels in CD8+ T 
cytotoxic cells in RA at 3-months follow-up of adalimumab treatment. B. Correlations between fold 
change in MC1-5R and IL-1β mRNA levels in CD4+ T helper cells in RA at 3-months follow-up of 
adalimumab treatment. Statistic: Spearman rank correlation test. P values <0.05 are considered 





Correlations between Fold Change in Resistin and TGF-β Gene 
Expressions (figure 5.6) 
There was a significant positive correlation between fold change in RETN and TGF-
β gene expressions in CD14+ monocytes, pointing at a relation between resistin gene 
expression and immune tolerance.  
 
Figure 5.6. Correlation between fold change in gene expression of resistin and transforming 
growth factor beta (TGF-β) in patients with active rheumatoid arthritis treated with TNF-α 
inhibition. Messenger RNAs were measured before and 3 months after start of treatment. 






7. DISCUSSION  
The studies in this thesis were aimed to find signs of activation of anti-
inflammatory, immune tolerance inducing, pro-resolving biologic systems  in human 
autoimmune, inflammatory disease. As the melanocortin system has only been very 
scarcely examined in human disease, we examined this system in active RA as it is 
known to possess tissue preserving, immune tolerance inducing qualities. We chose 
to measure adalimumab induced fold change in MC1-5R gene expressions in cell 
subsets of the adaptive and innate immune system. Moreover, in the same 
experiments we explored RETN gene expression as RETN has been suggested to 
play a role in the induction of Tregs. 
The effects of adalimumab on the immune system in active RA is to 
dampen and normalize a pathogenetic immune process. Thus, in RA patients 
responding to three months of adalimumab therapy, immune markers are expected to 
have approached normality. The favorable effects are evidenced by the fact that 
adalimumab treatment prevents joint destruction in responding patients (REF).  
Evidence of regulation of the melanocortin system and resistin in immune cells 
in RA  
Concerning the melanocortin system, we found that adalimumab 
treatment induced a decrease in MC1-5R gene expressions in all examined immune 
cell subsets, except for MC1R in CD4+ Th cells. The production of melanocortins, 
that is of ɑ-, β-, γ-MSH and ACTH is upregulated by inflammatory cytokines, 
especially TNFɑ and inhibited by TGFβ. Melanocortins in turn upregulate MCR 
 
60 
expression. Our findings indicate upregulation of the melanocortin system in active 
RA, approaching the resting state upon adalimumab treatment.  
In CD8+ Tc cells and CD19+ B-cells, adalimumab caused a 
significant decrease in MC2,3,4R gene expressions, pointing at a special role for 
MC2,3,4Rs in the function of these cell subsets. Even MC5R gene expression 
decreased significantly in CD19+ B-cells. The anti-inflammatory actions of MC3R 
activity in monocytes are well-known from animal experimental studies of urate 
crystal induced peritonitis and arthritis (Getting 2002, 2003). In experimental murine 
uveoretinitis, immune tolerance was induced by stimulating MC5R on CD4+ Th 
cells with ɑ-MSH, while the specific antigen was presented to these on DCs. This 
maneuver turned effector CD4+ Th cells cells into TGFβ secreting CD4+CD25+ 
Tregs (Taylor 2001). Our finding of significant reactions of MC2-5R gene 
expressions in B cells to TNFαI, points at a path to the transformation of 
pathogenetic B cell functions in RA. Promisingly, melanocortins have been shown 
to decrease kidney damage in lupus mice, by influencing B-cell activities such as 
ANA- and overall immunoglobulin production (Botte 2014).  
Resistin is a recently discovered cytokine, the effects of which are still only 
sporadically described. Surprisingly, RETN seems able to elicit seemingly opposing 
effects, that is exert pro-inflammatory, pro-fibrotic as well as immune tolerance and 
pro-resolving actions. The suspicion of pro-fibrotic qualities was based on a 
correlation between myocardial RETN and TGFβ gene expressions in a model of 
fibrosis and the ability of RETN to induce connective tissue growth factor (CTGF) 
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synthesis (Chemaly 2013). However most interesting, Son et al showed that 
treatment of a co-culture of CD4+ T cells and DC with RETN resulted in enhanced 
differentiation of CD4+ T cells into CD4+CD25+ Tregs (Son 2010). 
We found RETN gene expression in all examined immune cell types 
in active RA, with far the highest levels in CD14+ monocytes. TNFɑI resulted in a 
significant fall in RETN gene expression in CD14+ monocytes and a rise in gene 
expression in the non-responding patient. In CD4+ Th cells there was a significant 
fall in RETN gene expression in RA responding to therapy, however, RETN gene 
expression also decreased in the non-responding patient. Thus, we found clear signs 
of regulation of RETN gene expression by TNFɑI in CD14+ monocytes in RA. Also 
in CD4+ Th cells, our results pointed at the regulation of RETN gene expression by 
the cytokine milieu, however the regulation may be more complex. 
Also, CD56+ NK cells from two patients with active RA were found 
to express MC1-5R genes. The role of the NK cell in RA is controversial. However, 
the number of CD56dim NK cells, with high cytotoxic capacity seems decreased in 
the blood, while the number of CD56high NK cells with high cytokine, especially 
IFNγ, secreting ability is increased in the inflamed synovium and synovial fluid 
(Flodström-Tullberg 2009, review). Thus, it seems that CD56+ NK cells may play an 
active role in RA. The signs, we found of an activated melanocortin system in NK 
cells in RA, indicates that the melanocortin system might become a valuable new 
target for the regulation of NK cell activity in RA. 
 
62 
Hopefully, as the MC3R preferentially binds γ-MSH and MC4R has 
a higher affinity for β-MSH than other MCRs (Wikberg 2004) these MCRs can be 
targeted by synthetic, superselective γ- and β -MSH analogues, respectively, in the 
future (Getting 2006). 
Signs of disease counteracting, pro-resolving roles for resistin and the 
melanocortin system in RA. 
Considering our findings, there seems to exist yet unexplored, inherent mechanisms 
of immune cell functioning, acting to counteract the pathogenetic mechanisms in 
RA.  
Interestingly, we found significant correlations between 
adalimumab induced fold change in MC1-5R- and Th1 response signature cytokine: 
IFNγ gene expressions in CD8+ Tc cells. Recently, the role of CD8+ Tc cells in RA 
has been highlighted by the finding that synovial invasion of just these cells in 
preclinical ACPA and/or RF positive individuals heralds overt RA (De Hair 2014). 
The fact that CD8+ Tc cells during their maturation increase IFNγ secretion to 
considerable amounts point at a role for Tc cells in immune response direction (Liu 
2004). The correlations, we found, are suggestive of common regulatory 
mechanisms of melanocortin system activation and IFNγ synthesis in CD8+ Tc cells 
in RA. 
Also in CD4+ Th cells, we found evidence that the regulation of melanocortin 
system activity might be closely related to important immune mechanisms in RA. 
Thus, in CD4+ Th cells, adalimumab induced fold changes in MC1,2,3,5R and IL-1β 
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gene expressions correlated significantly. As the CD4+ Th cell is the classical helper 
cell, which directs the immune response exploiting differentiated cytokine synthesis, 
melanocortin system activity may be linked to disease driving mechanisms. The 
recent finding that IL-1β may exert Th1 cytokine functions, supports this notion 
(Bruchard 2015).  
In CD14+ monocytes, we found a significant correlation between 
adalimumab induced fold change in RETN and TGFβ gene expressions. In the light 
of the finding of a connection between RETN stimulated monocyte derived DCs and 
the differentiation of Tregs (Son 2010), our finding is interesting, yet, the meaning 
still unexamined and unclear. 
In summary, we found signs of activation and regulation of the 
melanocortin and RETN pathways in leukocyte subsets of both innate and adaptive 
immunity in RA. Both these pathways have immune tolerance inducing, pro-
resolving and anti-inflammatory potential, yet in the natural course of RA, their 
efforts were not powerful enough to resolve the disease. Our results, however, show 






8. CONCLUSIONS  
➢ The melanocortin system is activated in RA, and responds to changes in 
cytokine environment. 
 
➢ The regulation of the melanocortin system is closely related to important 
pathogenetic mechanisms in RA. 
 
 
➢ Resistin gene expression is regulated in monocytes and T helper cells in 
RA and responds to changes in cytokine milieu. 
 
➢ The regulation of resistin is related to TGF-β gene expression in monocytes 
in RA, pointing at a regulatory function. 
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